Living cell technologies: finding a path to market for xenotransplantation therapy
by Lisa Callagher; Brian Karlson; Nadine France; Cristiano Bellavitis
International Journal of Technology Transfer and Commercialisation (IJTTC), Vol. 16, No. 1, 2018

Abstract: This case examines the research commercialisation process of biotech company living cell technologies (LCT). The case outlines the process of pre-clinical and clinical trials undertaken by the company as they moved towards commercialising their pig islet cell treatment for Type 1 diabetes including the R&D and manufacturing capabilities the firm has developed. Also, the case describes the challenges in bringing a sometimes controversial biotech product to market, including regulatory hurdles; rapid changes to legislation; the impact of public opinion; and the difficulties in raising capital, maintaining cash flow and developing a pipeline of opportunities over a long period of commercialisation.

Online publication date: Tue, 26-Jun-2018

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Transfer and Commercialisation (IJTTC):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com